Linkster Therapeutics AG acts in the service of science to develop a new generation of targeted therapeutics for patients with illnesses that have no good treatment. The seegerlab is birthplace of two groundbreaking technologies differentiating the company from all other companies in the pharmaceutical market. Both the flycode technology and sybody platform laid the foundation of a true innovation of antibody selection and protein engineering. During their tenure at the seegerlab, Iwan Zimmermann and Pascal Egloff successfully enabled a number of academic and big pharma drug discovery projects by selecting conformation-specific sybodies against challenging membrane proteins such as SLC transporters. In 2019, Linkster Therapeutics AG was founded as a drug development company revolutionizing in vivo antibody development to create precision medicines for the right target, the right tissue & the right patient.

Learn more about Linkster Therapeutics

We are looking forward to your questions.